Compare CMPR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | ANAB |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2005 | 2015 |
| Metric | CMPR | ANAB |
|---|---|---|
| Price | $58.04 | $46.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $105.50 | $87.25 |
| AVG Volume (30 Days) | 250.4K | ★ 404.9K |
| Earning Date | 10-28-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 553.45 | 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,736,643,000.00 | $234,603,000.00 |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $4.80 | $69.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 9.80 | ★ 157.01 |
| 52 Week Low | $55.47 | $32.20 |
| 52 Week High | $106.58 | $73.30 |
| Indicator | CMPR | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 27.46 | 43.36 |
| Support Level | N/A | $44.25 |
| Resistance Level | $75.16 | $51.70 |
| Average True Range (ATR) | 4.58 | 1.81 |
| MACD | -1.62 | -0.00 |
| Stochastic Oscillator | 1.76 | 24.96 |
Cimpress PLC helps millions of businesses build brands, stand out, and grow via customized physical marketing products and branded merchandise. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. It has five segments VistaPrint, PrintBrothers, The Print Group, National Pen, and All Other Businesses. Majority of revenue comes from VistaPrint segment which provides graphic design services, VistaCreate for do-it-yourself (DIY) design, etc. It has presence in North America, Europe, and Other. The company generates majority of revenue is from Europe.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).